The Fourth School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou First People's Hospital, Hangzhou, Zhejiang, China.
Department of Oncological Surgery, Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou, China.
Hum Vaccin Immunother. 2024 Dec 31;20(1):2403170. doi: 10.1080/21645515.2024.2403170. Epub 2024 Sep 18.
Thyroid cancer is a common endocrine malignancy that poses considerable therapeutic challenges in treating anaplastic carcinoma and advanced aggressive disease. Immunotherapy has become a prominent strategy for cancer treatment, and has shown remarkable advancements in recent years. In this study, we utilized visualization and bibliometric tools to analyze publications on thyroid cancer immunotherapy from the Web of Science Core Collection (WoSCC). A total of 409 articles were included, with an annual increase in both publications and citations since 2016. China leads research efforts in this area, while the University of Texas System and UTMD Anderson Cancer Center rank first in publication output. The journal has garnered the highest citations. Notable authors contributing to this field include Antonelli Alessandro, Fallahi Poupak, and Wang Yu. Current research hotspots include immune checkpoint inhibitors, combination therapies involving immunotherapy with targeted therapy, CAR-T cell therapy, and modulation of the tumor microenvironment, all of which underscore the evolving landscape and potential for innovative treatments in thyroid cancer.
甲状腺癌是一种常见的内分泌恶性肿瘤，在治疗间变性癌和晚期侵袭性疾病方面存在相当大的治疗挑战。免疫疗法已成为癌症治疗的重要策略，近年来取得了显著进展。在这项研究中，我们利用可视化和文献计量学工具分析了来自 Web of Science 核心合集（WoSCC）的甲状腺癌免疫治疗的出版物。共纳入 409 篇文章，自 2016 年以来，出版物和引文数量逐年增加。中国在该领域的研究处于领先地位，而德克萨斯大学系统和 MD 安德森癌症中心在发表量方面排名第一。该期刊获得了最高的引用量。对该领域有贡献的知名作者包括 Antonelli Alessandro、Fallahi Poupak 和 Wang Yu。当前的研究热点包括免疫检查点抑制剂、免疫疗法与靶向治疗联合治疗、CAR-T 细胞疗法以及肿瘤微环境的调节，所有这些都强调了甲状腺癌治疗领域的不断发展和创新治疗的潜力。
